Sold as Gantanol, Gantanol-Ds. Every FDA application for this active ingredient: 2 branded and 7 generic.
As of Nov 15, 2026, FDA lists 9 applications for Sulfamethoxazole (sold as Gantanol, Gantanol-Ds), first approved Jul 1, 1965, with 0 new uses approved and 0 published complete response letters.
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma · Merck Sharp & Dohme LLC | Phase 2 / Phase 3 | Not yet recruiting | Nov 5, 2026 |
| Drug-induced Crystalluria in Sulfamethoxazole, High Dose Ciprofloxacin and High Dose AmoxicillinDrug-induced Crystalline Nephropathy, Drug-induced Crystalluria · Universitair Ziekenhuis Brussel | Not applicable | Recruiting | Aug 19, 2026 |
| Zuberitamab in the First Episode of Paediatric Nephrotic SyndromeNephrotic Syndrome · Children's Hospital of Fudan University | Phase 3 | Not yet recruiting | Aug 14, 2026 |
| TMP-SMX for Non-HIV PCP: A Prospective Multicenter StudyPneumocystis Jirovecii Pneumonia in Non-HIV Patients · Second Affiliated Hospital, Zhejiang University, School of Medicine | — | Not yet recruiting | Jul 8, 2026 |
| Precision Management of Urinary Tract Symptoms in Older WomenUrinary Tract Infection (Diagnosis) · Megan Bradley | Phase 3 | Recruiting | Jul 7, 2026 |
| Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPDChronic Obstructive Pulmonary Disease (COPD) · Second Affiliated Hospital, Zhejiang University, School of Medicine | Not applicable | Not yet recruiting | Jun 24, 2026 |
| Self-Start Triage Model for Post-Botox® Lower Urinary Tract SymptomsOveractive Bladder · The Cleveland Clinic | Early phase 1 | Recruiting | Jun 15, 2026 |
| Low- vs Standard-Dose TMP-SMX for Prevention of Pneumocystis Pneumonia After Kidney TransplantationPneumocystis Jirovecii Pneumonia, Kidney Transplantation · Anhui Provincial Hospital | Phase 4 | Not yet recruiting | Jun 1, 2026 |
| Jul 1, 1965 | GantanolNDA 13664 · New formulation or manufacturer | Roche | 3 | Discontinued |
| Aug 25, 1965 | Gantanol, Gantanol-DsNDA 12715 · New molecular entity | Roche | 6 | Discontinued |
| Mar 23, 1978 | SulfamethoxazoleANDA 85844 | Rising | 12 | Discontinued |
| Jul 25, 1983 | SulfamethoxazoleANDA 87189 | Barr | 0 | Discontinued |
| — | SulfamethoxazoleANDA 85053 | Watson Labs | 0 | Discontinued |
| — | SulfamethoxazoleANDA 86000 | Watson Labs | 0 | Discontinued |
| — | SulfamethoxazoleANDA 86163 | Heather | 0 | Discontinued |
| — | UrobakANDA 87307 | Shionogi | 0 | Discontinued |
| — | SulfamethoxazoleANDA 87662 | Ascot | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA